Jefferies Group Research Analysts Increase Earnings Estimates for United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) – Research analysts at Jefferies Group raised their FY2018 earnings estimates for United Therapeutics Corporation in a research note issued to investors on Wednesday. Jefferies Group analyst E. Yang now forecasts that the biotechnology company will post earnings per share of $11.41 for the year, up from their prior forecast of $11.37. Jefferies Group has a “Sell” rating and a $105.00 price objective on the stock. Jefferies Group also issued estimates for United Therapeutics Corporation’s FY2019 earnings at $10.62 EPS, FY2020 earnings at $10.53 EPS and FY2021 earnings at $10.72 EPS.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping the consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million for the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the firm posted $4.23 earnings per share.

ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/28/jefferies-group-research-analysts-increase-earnings-estimates-for-united-therapeutics-corporation-uthr.html.

Other research analysts also recently issued reports about the company. ValuEngine upgraded United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. TheStreet downgraded United Therapeutics Corporation from a “b-” rating to a “c” rating in a research report on Friday, September 29th. HC Wainwright reiterated a “hold” rating and set a $95.00 target price on shares of United Therapeutics Corporation in a research report on Thursday. Finally, Zacks Investment Research upgraded United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. Five analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $132.82.

United Therapeutics Corporation (NASDAQ UTHR) traded up 0.80% on Thursday, hitting $120.05. 462,617 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $120.33 and a 200-day moving average price of $125.64. United Therapeutics Corporation has a 12 month low of $112.01 and a 12 month high of $169.89. The stock has a market cap of $5.22 billion, a P/E ratio of 13.92 and a beta of 1.49.

In related news, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the sale, the director now directly owns 3,295 shares in the company, valued at $443,111.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,263 shares of the firm’s stock in a transaction on Thursday, October 26th. The stock was sold at an average price of $120.38, for a total value of $152,039.94. Following the completion of the sale, the chief executive officer now owns 1,403 shares of the company’s stock, valued at $168,893.14. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,368 shares of company stock valued at $2,295,419. 7.80% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in UTHR. Stifel Financial Corp increased its stake in United Therapeutics Corporation by 49.1% in the first quarter. Stifel Financial Corp now owns 3,073 shares of the biotechnology company’s stock worth $412,000 after purchasing an additional 1,012 shares during the period. OppenheimerFunds Inc. increased its stake in United Therapeutics Corporation by 24.8% in the first quarter. OppenheimerFunds Inc. now owns 2,881 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 573 shares during the period. Teachers Advisors LLC increased its stake in United Therapeutics Corporation by 17.0% in the first quarter. Teachers Advisors LLC now owns 91,328 shares of the biotechnology company’s stock worth $12,364,000 after purchasing an additional 13,239 shares during the period. PNC Financial Services Group Inc. increased its stake in United Therapeutics Corporation by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 95 shares during the period. Finally, Thrivent Financial For Lutherans increased its stake in United Therapeutics Corporation by 16.4% in the first quarter. Thrivent Financial For Lutherans now owns 8,430 shares of the biotechnology company’s stock worth $1,141,000 after purchasing an additional 1,190 shares during the period.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply